News
10h
Zacks Investment Research on MSNHere's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings
Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...
Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...
Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain ...
The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...
Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient ...
In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...
The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...
Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...
Hosted on MSN11mon
Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View - MSN
Pfizer PFE reported second-quarter 2024 adjusted earnings per share of 60 cents, which comfortably beat the Zacks Consensus Estimate of 45 cents per share. Earnings declined 11% year over year due ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results